Caricamento...
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...
Salvato in:
| Pubblicato in: | J Invest Dermatol |
|---|---|
| Autori principali: | , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4567913/ https://ncbi.nlm.nih.gov/pubmed/26016894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.198 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|